Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.67 |
| ▸ | MC4R | P32245 | 1/20 | 0.61 |
| ▸ | KDM1A | O60341 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11347486 | 0.89 | SIGMAR1 (0.72) | CCR3SIGMAR1MC4RDRD4LMNA | |
| SCHEMBL3037947 | 0.89 | SIGMAR1 (0.72) | CCR3SIGMAR1MC4RDRD4LMNA | |
| SCHEMBL6657455 | 0.88 | CCR3 (0.85) | CCR3SIGMAR1MC4RKDM1ADRD4 | |
| SCHEMBL6659913 | 0.88 | CCR3 (0.79) | CCR3SIGMAR1MC4RKDM1ADRD4 | |
| Hydrochloric Acid SCHEMBL10502885 | 0.86 | CCR3 (0.76) | CCR3SIGMAR1MC4RKDM1ADRD4 | |
| SCHEMBL6657649 | 0.86 | CCR3 (0.82) | CCR3SIGMAR1MC4RDRD4LMNA | |
| SCHEMBL11399131 | 0.85 | SIGMAR1 (0.81) | CCR3SIGMAR1POLB | |
| SCHEMBL10932016 | 0.85 | SIGMAR1 (0.69) | CCR3SIGMAR1 | |
| SCHEMBL8186010 | 0.85 | CCR3 (0.51) | CCR3SIGMAR1MC4RLMNAPOLB | |
| SCHEMBL6659339 | 0.84 | SIGMAR1 (0.86) | CCR3SIGMAR1MC4RDRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148541-B2 | Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2012-04-03 | — | — | US | disclosed |
| WO-2010025906-A2 | HYBRID ANTIMICROBIAL COMPOUNDS AND THEIR USE | MERLION PHARMACEUTICALS PTE LTD (SG) | 2010-03-11 | — | — | WO | disclosed |
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2009-02-12 | — | — | US | disclosed |
| WO-2007081091-A1 | RHODANDSE DERIVARIVES, A PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) | 2007-07-19 | — | — | WO | disclosed |
| EP-0928789-B1 | 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ONE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | NIKKEN CHEMICALS CO LTD (JP) | 2004-09-29 | — | — | EP | disclosed |
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| US-6251897-B1 | TREATING DERMATITIS, ASTHMA | NIKKEN CHEMICALS CO., LTD (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
| EP-0928789-A1 | 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ONE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-07-14 | — | — | EP | disclosed |
| EP-0050396-B1 | COUMARIN INTERMEDIATES | BEECHAM GROUP PLC (GB) | 1984-12-27 | — | — | EP | disclosed |
| EP-0010392-B1 | HETEROCYCLIC COUMARIN DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID DERIVATIVES | BEECHAM GROUP PLC (GB) | 1982-12-29 | — | — | EP | disclosed |
| EP-0050396-A1 | Coumarin intermediates | BEECHAM GROUP PLC (GB) | 1982-04-28 | — | — | EP | disclosed |
| US-4263299-A | ANTIHISTAMINES, ANTIALLERGENS | BEECHAM GROUP LIMITED (GB) | 1981-04-21 | — | — | US | disclosed |
| EP-0010392-A1 | Heterocyclic coumarin derivatives, their preparation and pharmaceutical compositions comprising said derivatives | BEECHAM GROUP PLC (GB) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042872-A1 | Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same | PTPRR, PTPRG, PTPRS | CCR3 1077/4885SIGMAR1 2456/4885MC4R 1395/4885 |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | CCR3 109/4885SIGMAR1 127/4885MC4R 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.